US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

245.93

+0.35000.14%

Post-market: 242.01-3.9200-1.59%16:36 EDT

Volume:180.79K

Turnover:44.27M

Market Cap:29.10B

PE:-66.41

High:248.00

Open:243.45

Low:240.00

Close:245.58

Loading ...

Overview Company News Filings

BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO

BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA

BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland

MT Newswires Live

Sector Update: Health Care

MT Newswires Live

BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use

BeiGene receives positive CHMP opinion for Tevimbra

Beigene's Cancer Drug Tevimbra Recommended by EU Panel for Extension of Indication

MT Newswires Live

Stock Track | BeiGene Plummets 5.60% in Pre-market as Trump's Drug Pricing Plan Rattles Pharma Stocks

Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks

Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs

BeiGene Is Maintained at Buy by Guggenheim

BeiGene price target raised to $350 from $348 at Guggenheim

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

MT Newswires Live

Beigene Ltd reports results for the quarter ended March 31 - Earnings Summary

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

Stock Track | BeiGene Plunges 5.25% Pre-Market Despite Strong Q1 Results and Maintained 2025 Guidance

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

MT Newswires Live

BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B

CORRECTION: BeiGene Q1 Adj. EPADS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $1.14B Estimate

Beigene Ltd expected to post a loss of 74 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ONC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":245.93,"timestamp":1748894400000,"preClose":245.58,"halted":0,"volume":180786,"hourTrading":{"tag":"盘后","latestPrice":242.01,"preClose":245.93,"latestTime":"16:36 EDT","volume":1712,"amount":421012.5576,"timestamp":1748896592268},"delay":0,"floatShares":75624000,"shares":118343200,"eps":-3.70325,"marketStatus":"Post-Mkt","change":0.35,"latestTime":"06-02 17:31:02 EDT","open":243.45,"high":248,"low":240,"amount":44267596.22196,"amplitude":0.032576,"askPrice":246,"askSize":3,"bidPrice":242,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1748908800000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":245.58,"preHourTrading":{"tag":"盘前","latestPrice":244.71,"preClose":245.58,"latestTime":"09:25 EDT","volume":8228,"amount":2020632.6514,"timestamp":1748870700016},"postHourTrading":{"tag":"盘后","latestPrice":242.01,"preClose":245.93,"latestTime":"16:36 EDT","volume":1712,"amount":421012.5576,"timestamp":1748896592268},"volumeRatio":0.645775,"impliedVol":0.4113,"impliedVolPercentile":0.2524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75624000,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.645775,"shares":118343200,"dividePrice":0,"high":248,"amplitude":0.032576,"preClose":245.58,"low":240,"week52Low":141.31,"pbRate":"8.32","psRate":"6.97","week52High":287.88,"institutionHeld":0,"latestPrice":245.93,"committee":0.454545,"eps":-3.70325,"divideRate":0,"volume":180786,"delay":0,"ttmEps":-3.70325,"open":243.45,"prevYearClose":184.71,"prevWeekClose":245.58,"prevMonthClose":245.58,"prevQuarterClose":272.17,"fiveDayClose":241.43,"twentyDayClose":255.77,"sixtyDayClose":256.97},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540676444","title":"BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2540676444","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540676444?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:15","pubTimestamp":1748859321,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology Annual Meet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0251131958.USD","LU2360106947.USD","ONC","BK4526","BK4139","BK4585","BK4588","LU0048573561.USD","LU0251142724.SGD","LU0471298694.HKD","LU0471298777.SGD","LU0742534661.SGD","BG","LU0385154629.USD","MDCO","BK4189","LU2211817866.USD"],"gpt_icon":0},{"id":"2540308077","title":"BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2540308077","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540308077?lang=en_us&edition=fundamental","pubTime":"2025-06-02 03:50","pubTimestamp":1748807415,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA. These data will ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4609","LU0348723411.USD","IE00BMPRXR70.SGD","BK4543","ONC","IE00BMPRXN33.USD","BK4526","BK4585","MDCO","BK4141","IE00BMPRXQ63.HKD"],"gpt_icon":0},{"id":"2538464563","title":"BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2538464563","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538464563?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:34","pubTimestamp":1748352847,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday it has changed its name to BeOne Medicines and completed its redomiciliation to Switzerland.The company said its shareholders approved the new name and redomiciliation to Switzerland from the Cayman Islands on April 28.The transition to its new name throughout its global operations will take effect in phases, the company added.BeOne's shares were up more than 1% in early trading Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","06160","MDCO","BK4526","ONC"],"gpt_icon":0},{"id":"2538646180","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2538646180","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538646180?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:01","pubTimestamp":1748350877,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Tuesday as the Health Care Select Sector SPDR Fund  was up 0.9% and the iShares Biotechnology ETF  rose by 1.1% recently.BeiGene  shares were slightly down after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug Tevimbra in combination with gemcitabine and cisplatin as a first-line treatment for adults with recurrent or metastatic nasopharyngeal cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BK4588","ONC","BK4581","BK4139","BK4585","IBB","BK4526"],"gpt_icon":0},{"id":"2538468004","title":"BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468004","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468004?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:12","pubTimestamp":1748344320,"startTime":"0","endTime":"0","summary":"BeiGene's Tevimbra gets a highly sought after recommendation.The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use  issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK1500","LU2328871848.SGD","BK1583","06160","CHMP","ONC","BK1588","BK4139","LU1969619763.USD","BK4526","LU0588546209.SGD","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2538445086","title":"BeiGene receives positive CHMP opinion for Tevimbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2538445086","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538445086?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:10","pubTimestamp":1748340648,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087","BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2537371571","title":"Beigene's Cancer Drug Tevimbra Recommended by EU Panel for Extension of Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2537371571","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537371571?lang=en_us&edition=fundamental","pubTime":"2025-05-23 22:13","pubTimestamp":1748009639,"startTime":"0","endTime":"0","summary":"The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it recommended an extension of therapeutic indication for Beigene's  cancer drug Tevimbra.Tevimbra is already authorized in the EU, the committee said, with indications for non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, and oesophageal squamous cell carcinoma.Price: 240.05, Change: +1.29, Percent Change: +0.54","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","BK4139","06160","BK4156","BK4526"],"gpt_icon":0},{"id":"1162268752","title":"Stock Track | BeiGene Plummets 5.60% in Pre-market as Trump's Drug Pricing Plan Rattles Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268752","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162268752?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:04","pubTimestamp":1747051447,"startTime":"0","endTime":"0","summary":"BeiGene Ltd.  shares plunged 5.60% in pre-market trading on Monday, following President Trump's announcement of an executive order aimed at lowering prescription drug costs in the United States. The move has sent shockwaves through the Asian pharmaceutical sector, with BeiGene among the hardest hit.The sharp decline comes after President Trump declared his intention to sign an executive order implementing a \"Most Favored Nation\" policy. This policy would tie U.S. government drug prices to those ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c16d71d2eba9cb3da9792d48223abc57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"1190598443","title":"Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1190598443","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190598443?lang=en_us&edition=fundamental","pubTime":"2025-05-12 10:04","pubTimestamp":1747015462,"startTime":"0","endTime":"0","summary":"BeiGene Ltd.  experienced a significant 24-hour plunge of 6.86% in the night session, as President Trump's announcement to lower prescription drug costs sent shockwaves through the Asian pharmaceutical sector.The decline comes in response to President Trump's declaration that he would sign an executive order implementing a \"Most Favored Nation\" policy. This policy aims to tie U.S. government drug prices to those paid by other countries, potentially affecting the profitability of pharmaceutical c","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"613df4b61bc3692be0fcc4204cdfad36","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"2534686492","title":"Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2534686492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534686492?lang=en_us&edition=fundamental","pubTime":"2025-05-12 10:01","pubTimestamp":1747015260,"startTime":"0","endTime":"0","summary":"Shares of Asia drugmakers fell on Monday after President Trump said he would sign an executive order aimed at lowering the cost of prescription drugs.Among Japanese drugmakers, many of which generate significant parts of their revenue in the U.S., share of Daiichi Sankyo were recently down 5.5%. Otsuka Holdings was 3.7% lower and Roche Holding's Japanese unit, Chugai Pharmaceutical, was down 6.0%.Revenue from the U.S. made up about a third of Daiichi Sankyo's total revenue for the fiscal year ended March. At Otsuka's pharmaceutical business, North America accounted for about a half of revenue in 2024.In Seoul, Daewoong Pharmaceutical was trading 4.6% lower, while Samsung Biologics fell 3.5% and Celltrion was down 3.7%.Pharma stocks were broadly weaker in China too, with BeiGene down 6.2% and Jiangsu Hengrui Medicine off by 2.9%. In Hong Kong, WuXi Biologics shed 4.1% and Hansoh Pharmaceutical lost 2.95%.President Trump on Sunday said he would be instituting a policy known as \"Most Favo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"613df4b61bc3692be0fcc4204cdfad36","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","BK1610","LU2148510915.USD","SG9999002562.SGD","LU0456827905.SGD","LU1064131003.USD","IE00B0JY6N72.USD","BK0188","LU0348735423.USD","LU0359201612.USD","LU0405327494.USD","LU0456846285.SGD","LU0516423091.SGD","BK4007","BK0196","BK1583","03165","LU0588546209.SGD","BK0060","LU2039709279.SGD","LU2488822045.USD","LU0516422440.USD","BK1576","BK4526","LU0405327148.USD","LU1328615791.USD","LU0417516738.SGD","RHHBY","02269","BK1191","LU0181495838.USD","LU0359202008.SGD","LU1794554557.SGD","LU0140636845.USD","BK0183","DSNKY","LU0823426308.USD","LU0516422366.SGD","BK1141","600276","03692","BK0239","LU0320764599.SGD","LU1720050803.USD","LU1969619763.USD","LU0572944931.SGD","LU0051755006.USD","LU0039217434.USD","ONC","SG9999002463.SGD"],"gpt_icon":1},{"id":"2533459132","title":"BeiGene Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2533459132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533459132?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:47","pubTimestamp":1746715620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 10:47 ET (14:47 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":0},{"id":"2533187470","title":"BeiGene price target raised to $350 from $348 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2533187470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533187470?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:39","pubTimestamp":1746707999,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $350 from $348 and keeps a Buy rating on the shares. The firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-price-target-raised-to-350-from-348-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-price-target-raised-to-350-from-348-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2533900520","title":"RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2533900520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533900520?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:50","pubTimestamp":1746701418,"startTime":"0","endTime":"0","summary":"BeiGene's (ONC) US stock has an average rating of buy and mean price target of $334.87, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2533930030","title":"Beigene Ltd reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533930030","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533930030?lang=en_us&edition=fundamental","pubTime":"2025-05-07 23:20","pubTimestamp":1746631242,"startTime":"0","endTime":"0","summary":"Beigene Ltd reports results for the quarter ended March 31 - Earnings SummaryBeigene Ltd ONC.OQ reported quarterly adjusted earnings of 1 cent per share for the quarter ended March 31, higher than the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF2JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235"],"gpt_icon":0},{"id":"2533937422","title":"Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2533937422","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533937422?lang=en_us&edition=fundamental","pubTime":"2025-05-07 23:01","pubTimestamp":1746630086,"startTime":"0","endTime":"0","summary":"BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/05/45257204/chinese-biotech-beigene-stock-falls-despite-strong-brukinsa-sales-and-earnings-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","AMGN","ONC"],"gpt_icon":0},{"id":"1171926967","title":"Stock Track | BeiGene Plunges 5.25% Pre-Market Despite Strong Q1 Results and Maintained 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1171926967","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171926967?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:49","pubTimestamp":1746622160,"startTime":"0","endTime":"0","summary":"BeiGene Ltd.  saw its stock price plummet 5.25% in pre-market trading on Wednesday, despite reporting strong first-quarter 2025 financial results and maintaining its full-year guidance. The global oncology company, which is set to change its name to BeOne Medicines Ltd., announced its Q1 performance and business updates after market close on Tuesday.Despite these positive results, investors seemed to focus on other aspects of the report. The company maintained its full-year 2025 revenue guidance","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | BeiGene Plunges 5.25% Pre-Market Despite Strong Q1 Results and Maintained 2025 Guidance","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"2533602172","title":"BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated","url":"https://stock-news.laohu8.com/highlight/detail?id=2533602172","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533602172?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:24","pubTimestamp":1746613496,"startTime":"0","endTime":"0","summary":"BeiGene  reported Q1 adjusted earnings Wednesday of $1.22 per diluted American depositary share, swinging from an adjusted loss of $1.40 a year earlier.Comparable analyst estimates were not readily available.Revenue for the quarter ended March 31 was $1.12 billion, up from $751.7 million a year earlier.Analysts surveyed by FactSet expected $1.13 billion.For 2025, the biotech company continues to expect revenue of $4.9 billion to $5.3 billion.Analysts polled by FactSet expect $5.07 billion.Shares of the company were down more than 5% in recent premarket activity.Price: 229.00, Change: -12.75, Percent Change: -5.27","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2533602667","title":"BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B","url":"https://stock-news.laohu8.com/highlight/detail?id=2533602667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533602667?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:20","pubTimestamp":1746613237,"startTime":"0","endTime":"0","summary":"06:19 EDT BeiGene (ONC) sees FY25 revenue $4.9B-$5.3B, consensus $5.09B Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-sees-fy25-revenue-4-9b-5-3b-consensus-5-09b?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-sees-fy25-revenue-4-9b-5-3b-consensus-5-09b?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2533040586","title":"CORRECTION: BeiGene Q1 Adj. EPADS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $1.14B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533040586","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533040586?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:11","pubTimestamp":1746612715,"startTime":"0","endTime":"0","summary":"CORRECTION: BeiGene Q1 Adj. EPADS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $1.14B Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45246969/correction-beigene-q1-adj-epads-1-22-beats-0-74-estimate-sales-1-12b-miss-1-14b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":0},{"id":"2533897085","title":"Beigene Ltd  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533897085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533897085?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:43","pubTimestamp":1746448985,"startTime":"0","endTime":"0","summary":"Beigene Ltd  expected to post a loss of74cents a share - Earnings Preview Beigene Ltd ONC.OQ, ONC.O is expected to show a rise in quarterly revenue when it reports  results on May 7 for the period end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":86,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3043,"buy":0.6522,"hold":0.0435,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6522,"analysts":23,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-30","current":-74.527648,"percent":0,"low":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"high":-19.234246,"avg":-35.196482,"sd":12.597577,"marketCap":29242115209},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209}],"updateTime":1748858974038}}}